{"url_path":"/sec/apm/8-k/2026-07-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1734005/0001213900-26-079416-index.html","accession_number":"0001213900-26-079416","cik":"0001734005","ticker":"APM","issuer_name":"Niki BioSolutions, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1734005/0001213900-26-079416-index.html","primary_entity_key":"0001734005","primary_entity_name":"Niki BioSolutions, Inc."},"word_count":132,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n** **\n\nOn July 16, 2026, Aptorum distributed a press release announcing the\nMerger and related actions. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated\nby reference herein.\n\n \n\nThis Form 8-K shall not\nconstitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Aptorum or DiamiR\nin any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under\nthe securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the\nrequirements of Section 10 of the Securities Act of 1933, as amended."}